Literature DB >> 20635880

Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer.

Debora Martorelli1, Elena Muraro, Anna Merlo, Riccardo Turrini, Antonio Rosato, Riccardo Dolcetti.   

Abstract

Our knowledge on the physiological role of CD4(+) T lymphocytes has improved in the last decade: available data convincingly demonstrate that, besides the 'helper' activity, CD4(+) T cells may be also endowed with lytic properties. The cytotoxic function of these effector cells has a relevant role in the control of pathogenic infections and in mediating antitumor immune responses. On these bases, several immunotherapeutic approaches exploiting the cytotoxic properties of CD4(+) T cells are under investigation. This review summarizes available data supporting the functional and therapeutic relevance of cytotoxic CD4(+) T cells, with a particular focus on Epstein-Barr virus (EBV)-related disorders.

Entities:  

Mesh:

Year:  2010        PMID: 20635880     DOI: 10.3109/08830185.2010.489658

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  23 in total

Review 1.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

2.  Toll-like receptor agonist rMBP-NAP enhances antitumor cytokines production and CTL activity of peripheral blood mononuclear cells from patients with lung cancer.

Authors:  Cong Ding; Li Li; Yi Zhang; Zhenyu Ji; Chenglong Zhang; Taotao Liang; Xun Guo; Xin Liu; Qiaozhen Kang
Journal:  Oncol Lett       Date:  2018-07-20       Impact factor: 2.967

3.  Cytosolic DNA-activated human dendritic cells are potent activators of the adaptive immune response.

Authors:  Katalin Kis-Toth; Attila Szanto; To-Ha Thai; George C Tsokos
Journal:  J Immunol       Date:  2011-06-27       Impact factor: 5.422

Review 4.  IgG4-related disease.

Authors:  Emanuele Bozzalla Cassione; John H Stone
Journal:  Curr Opin Rheumatol       Date:  2017-05       Impact factor: 5.006

5.  HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.

Authors:  W Herr; Y Eichinger; J Beshay; A Bloetz; S Vatter; C Mirbeth; E Distler; U F Hartwig; S Thomas
Journal:  Leukemia       Date:  2016-08-01       Impact factor: 11.528

6.  CD4 T cells specific for a latency-associated γ-herpesvirus epitope are polyfunctional and cytotoxic.

Authors:  Michael L Freeman; Claire E Burkum; Tres Cookenham; Alan D Roberts; Kathleen G Lanzer; Gail E Huston; Meghan K Jensen; John Sidney; Bjoern Peters; Jacob E Kohlmeier; David L Woodland; Linda F van Dyk; Alessandro Sette; Marcia A Blackman
Journal:  J Immunol       Date:  2014-11-05       Impact factor: 5.422

7.  Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro.

Authors:  Camilla A Lindqvist; Lisa H Christiansson; Ingrid Thörn; Sara Mangsbo; Gabriella Paul-Wetterberg; Christer Sundström; Thomas H Tötterman; Bengt Simonsson; Gunilla Enblad; Per Frisk; Ulla Olsson-Strömberg; Angelica S I Loskog
Journal:  Immunology       Date:  2011-04-05       Impact factor: 7.397

8.  Human CD4+ T cell response to human herpesvirus 6.

Authors:  Maria-D Nastke; Aniuska Becerra; Liusong Yin; Omar Dominguez-Amorocho; Laura Gibson; Lawrence J Stern; J Mauricio Calvo-Calle
Journal:  J Virol       Date:  2012-02-22       Impact factor: 5.103

9.  Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation.

Authors:  Ulrike Gerdemann; Laura Keukens; Jacqueline M Keirnan; Usha L Katari; Chinh T Q Nguyen; Anne P de Pagter; Carlos A Ramos; Alana Kennedy-Nasser; Stephen M Gottschalk; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Ann M Leen
Journal:  Blood       Date:  2012-11-14       Impact factor: 22.113

Review 10.  CD4 CTL: living up to the challenge.

Authors:  Hilde Cheroutre; Mohammad Mushtaq Husain
Journal:  Semin Immunol       Date:  2013-11-15       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.